Synthesis, kinetics, mechanisms, and bioactivity evaluations of a novel Zn(ii) complex

Anwesha Dey; Ramesh Kumar; Bhramar Dutta; Rajib Bandopadhyay; Sankha Chakrabortty; Moonis Ali Khan; Rijuta Ganesh Saratale; Ganesh Dattatraya Saratale; Byong Hun Jeon; Alak K. Ghosh

doi:10.1039/d4ra03356f

Synthesis, kinetics, mechanisms, and bioactivity evaluations of a novel Zn(ii) complex

Anwesha Dey
, Ramesh Kumar
, Bhramar Dutta
, Rajib Bandopadhyay
, Sankha Chakrabortty
, Moonis Ali Khan
, Rijuta Ganesh Saratale
, Ganesh Dattatraya Saratale
, Byong Hun Jeon
, Alak K. Ghosh

University of Burdwan
Hanyang University
Kalinga Institute of Industrial Technology
King Saud University

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Zn(ii)-based anticancer drugs can be suitable alternatives to conventional Pt(ii)-based drugs because of the unique chemical properties of Zn(ii) and low toxicity. In this study, a new hexadentate and heteroleptic Zn(ii) complex ([Zn(bpy)₂(OAc)₂], 1) was prepared with a conventional N,N-donor ligand (2,2′-bipyridine) and a leaving group (OAc) and characterized via ESI-MS, UV-Vis, and FT-IR spectroscopy. Kinetic and mechanistic investigations of 1 were performed using two biologically relevant ligands (dl-penicillamine and l-cysteine) to understand its selectivity and reactivity. Substitution reactions were determined to be two-step processes in the associative activation mode. Bioactivity studies of 1 revealed moderate to strong DNA-binding, cleaving ability, and antimicrobial properties.

Original language	English
Pages (from-to)	28693-28702
Number of pages	10
Journal	RSC Advances
Volume	14
Issue number	39
DOIs	https://doi.org/10.1039/d4ra03356f
State	Published - 10 Sep 2024

Access to Document

10.1039/d4ra03356f

Cite this

@article{94da7784639340139e030f9b1a2d59ae,

title = "Synthesis, kinetics, mechanisms, and bioactivity evaluations of a novel Zn(ii) complex",

abstract = "Zn(ii)-based anticancer drugs can be suitable alternatives to conventional Pt(ii)-based drugs because of the unique chemical properties of Zn(ii) and low toxicity. In this study, a new hexadentate and heteroleptic Zn(ii) complex ([Zn(bpy)2(OAc)2], 1) was prepared with a conventional N,N-donor ligand (2,2′-bipyridine) and a leaving group (OAc) and characterized via ESI-MS, UV-Vis, and FT-IR spectroscopy. Kinetic and mechanistic investigations of 1 were performed using two biologically relevant ligands (dl-penicillamine and l-cysteine) to understand its selectivity and reactivity. Substitution reactions were determined to be two-step processes in the associative activation mode. Bioactivity studies of 1 revealed moderate to strong DNA-binding, cleaving ability, and antimicrobial properties.",

author = "Anwesha Dey and Ramesh Kumar and Bhramar Dutta and Rajib Bandopadhyay and Sankha Chakrabortty and Khan, \{Moonis Ali\} and Saratale, \{Rijuta Ganesh\} and Saratale, \{Ganesh Dattatraya\} and Jeon, \{Byong Hun\} and Ghosh, \{Alak K.\}",

note = "Publisher Copyright: {\textcopyright} 2024 The Royal Society of Chemistry.",

year = "2024",

month = sep,

day = "10",

doi = "10.1039/d4ra03356f",

language = "English",

volume = "14",

pages = "28693--28702",

journal = "RSC Advances",

issn = "2046-2069",

publisher = "Royal Society of Chemistry",

number = "39",

}

TY - JOUR

T1 - Synthesis, kinetics, mechanisms, and bioactivity evaluations of a novel Zn(ii) complex

AU - Dey, Anwesha

AU - Kumar, Ramesh

AU - Dutta, Bhramar

AU - Bandopadhyay, Rajib

AU - Chakrabortty, Sankha

AU - Khan, Moonis Ali

AU - Saratale, Rijuta Ganesh

AU - Saratale, Ganesh Dattatraya

AU - Jeon, Byong Hun

AU - Ghosh, Alak K.

PY - 2024/9/10

Y1 - 2024/9/10

N2 - Zn(ii)-based anticancer drugs can be suitable alternatives to conventional Pt(ii)-based drugs because of the unique chemical properties of Zn(ii) and low toxicity. In this study, a new hexadentate and heteroleptic Zn(ii) complex ([Zn(bpy)2(OAc)2], 1) was prepared with a conventional N,N-donor ligand (2,2′-bipyridine) and a leaving group (OAc) and characterized via ESI-MS, UV-Vis, and FT-IR spectroscopy. Kinetic and mechanistic investigations of 1 were performed using two biologically relevant ligands (dl-penicillamine and l-cysteine) to understand its selectivity and reactivity. Substitution reactions were determined to be two-step processes in the associative activation mode. Bioactivity studies of 1 revealed moderate to strong DNA-binding, cleaving ability, and antimicrobial properties.

AB - Zn(ii)-based anticancer drugs can be suitable alternatives to conventional Pt(ii)-based drugs because of the unique chemical properties of Zn(ii) and low toxicity. In this study, a new hexadentate and heteroleptic Zn(ii) complex ([Zn(bpy)2(OAc)2], 1) was prepared with a conventional N,N-donor ligand (2,2′-bipyridine) and a leaving group (OAc) and characterized via ESI-MS, UV-Vis, and FT-IR spectroscopy. Kinetic and mechanistic investigations of 1 were performed using two biologically relevant ligands (dl-penicillamine and l-cysteine) to understand its selectivity and reactivity. Substitution reactions were determined to be two-step processes in the associative activation mode. Bioactivity studies of 1 revealed moderate to strong DNA-binding, cleaving ability, and antimicrobial properties.

UR - https://www.scopus.com/pages/publications/85204184589

U2 - 10.1039/d4ra03356f

DO - 10.1039/d4ra03356f

M3 - Article

AN - SCOPUS:85204184589

SN - 2046-2069

VL - 14

SP - 28693

EP - 28702

JO - RSC Advances

JF - RSC Advances

IS - 39

ER -

Synthesis, kinetics, mechanisms, and bioactivity evaluations of a novel Zn(ii) complex

Abstract

Access to Document

Other files and links

Fingerprint

Cite this